Rezpira

Rezpira

salmeterol + fluticasone

Manufacturer:

ACME

Distributor:

Euro Generics

Marketer:

Bell-Kenz Pharma
Concise Prescribing Info
Contents
Per 25 mcg/250 mcg/actuation MDI Salmeterol xinafoate 25 mcg, fluticasone propionate 250 mcg
Indications/Uses
Regular treatment of asthma, where use of a combination product (long-acting β2 agonist & inhaled corticosteroid) is appropriate. Patients not adequately controlled w/ inhaled corticosteroids & as needed inhaled short acting β2 agonist; already adequately controlled on both inhaled corticosteroid & long-acting β2 agonist.
Dosage/Direction for Use
Adult including elderly & adolescent >12 yr 2 puffs bid.
Contraindications
Special Precautions
Do not use to treat acute asthma symptoms for which fast & short-acting bronchodilator is required. Do not stop treatment abruptly. Patients w/ active or quiescent pulmonary TB & severe thyrotoxicosis. Pregnancy & lactation. May reduce growth velocity in childn.
Adverse Reactions
Salmeterol xinafoate: Tremor, subjective palpitations & headache. Cardiac arrhythmias; Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, cataract & glaucoma. Fluticasone propionate: Hoarseness & candidiasis (thrush) of the mouth & throat.
ATC Classification
R03AK06 - salmeterol and fluticasone ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Rezpira 25 mcg/250 mcg/actuation MDI
Packing/Price
120 actuation x 1's (P600/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in